ArticleBMC pharmacology & toxicology2025
Metallic nanoparticles in the treatment of staphylococcus infections: a scoping review.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfectious diseases constitute a serious public health problem and Staphylococcus species are one of the major pathogens that cause infectious diseases. This review aims to identify metallic nanoparticles used to combat Staphylococcus infections.
methodsIn this study, three (3) electronic databases (Google Scholar, PubMed, and Science Direct) were used to search for relevant literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) flow chart.
resultsA total of 35 studies were included in this review. Results showed that silver nanoparticles (AgNPs) were the predominant metallic nanoparticles used for combating Staphylococcus based infections. Other metallic nanoparticles include copper nanoparticles (CuNPs), selenium nanoparticles (SeNPs), aluminum nanoparticles (AlNPs), gold nanoparticles (AuNPs), Nickel nanoparticles (NiNPs), and vanadium nanoparticles (VanNPs). Also, UV-visible spectroscopy was the most frequently reported characterization method, followed by Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), and X-Ray Diffraction (XRD). In the included studies, antimicrobial activities were evaluated using zone of inhibition (ZOI) and minimum inhibitory concentration (MIC) values. Reported ZOI in the various studies ranged from 4.7 mm to 32 mm, with MIC values generally between 0.25–3125 µg/mL.
conclusionsIn conclusion, whereas metallic nanomaterials, particularly copper and silver nanoparticles, have promising antibacterial properties against drug-resistant strains of Staphylococcus aureus, more thorough and consistent reporting is obviously required in subsequent research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.